| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Neurocrine Biosciences Inc (NASDAQ: NBIX)
NBIX Technical Analysis
2
| As on 9th Jun 2023 NBIX SHARE Price closed @ 93.39 and we RECOMMEND Sell for LONG-TERM with Stoploss of 96.34 & Strong Buy for SHORT-TERM with Stoploss of 82.46 we also expect STOCK to react on Following IMPORTANT LEVELS. |
NBIXSHARE Price
| Open | 94.03 | Change | Price | % |
| High | 94.32 | 1 Day | -0.64 | -0.68 |
| Low | 93.11 | 1 Week | 3.86 | 4.31 |
| Close | 93.39 | 1 Month | -8.51 | -8.35 |
| Volume | 437100 | 1 Year | 8.72 | 10.30 |
| 52 Week High 127.06 | 52 Week Low 72.45 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| NBIX Daily Charts |
NBIX Intraday Charts |
Whats New @ Bazaartrend |
NBIX Free Analysis |
|
|
NBIX Important Levels Intraday
| RESISTANCE | 95.72 |
| RESISTANCE | 94.97 |
| RESISTANCE | 94.51 |
| RESISTANCE | 94.05 |
| SUPPORT | 92.73 |
| SUPPORT | 92.27 |
| SUPPORT | 91.81 |
| SUPPORT | 91.06 |
NBIX Forecast April 2024
| 4th UP Forecast | 124.4 |
| 3rd UP Forecast | 114.45 |
| 2nd UP Forecast | 108.31 |
| 1st UP Forecast | 102.16 |
| 1st DOWN Forecast | 84.62 |
| 2nd DOWN Forecast | 78.47 |
| 3rd DOWN Forecast | 72.33 |
| 4th DOWN Forecast | 62.38 |
NBIX Weekly Forecast
| 4th UP Forecast | 104.49 |
| 3rd UP Forecast | 100.93 |
| 2nd UP Forecast | 98.73 |
| 1st UP Forecast | 96.53 |
| 1st DOWN Forecast | 90.25 |
| 2nd DOWN Forecast | 88.05 |
| 3rd DOWN Forecast | 85.85 |
| 4th DOWN Forecast | 82.29 |
NBIX Forecast2024
| 4th UP Forecast | 204.02 |
| 3rd UP Forecast | 168.54 |
| 2nd UP Forecast | 146.61 |
| 1st UP Forecast | 124.68 |
| 1st DOWN Forecast | 62.1 |
| 2nd DOWN Forecast | 40.17 |
| 3rd DOWN Forecast | 18.24 |
| 4th DOWN Forecast | -17.24 |
Neurocrine Biosciences Inc ( NASDAQ USA Symbol : NBIX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
NBIX Business Profile
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL ? Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California. Address: 12780 El Camino Real, San Diego, CA, United States, 92130
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service